A Phase 1, Open-Label Study To Evaluate 5-HT6 Receptor Occupancy As Measured By Positron Emission Tomography (Pet) With Ligand [11C]PF-04171252 Following Single Oral Dose Administration Of PF-05212365 (SAM-531) In Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 07 Oct 2011
At a glance
- Drugs Cerlapirdine (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- 07 Oct 2011 PF 05212365 is called cerlapirdine.
- 21 Dec 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 13 Dec 2010 New trial record